TNBC Therapeutics Based on Combination of Fusarochromanone with EGFR Inhibitors

Fusarochromanone is an experimental drug with unique and potent anti-cancer activity. Current cancer therapies often incorporate a combination of drugs to increase efficacy and decrease the development of drug resistance. In this study, we used drug combinations and cellular phenotypic screens to ad...

Descripción completa

Detalles Bibliográficos
Autores principales: Carroll, Natalie, Youngblood, Reneau, Smith, Alena, Dragoi, Ana-Maria, Salvatore, Brian A., Mahdavian, Elahe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9687139/
https://www.ncbi.nlm.nih.gov/pubmed/36428475
http://dx.doi.org/10.3390/biomedicines10112906

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9687139/
https://www.ncbi.nlm.nih.gov/pubmed/36428475
http://dx.doi.org/10.3390/biomedicines10112906

Ejemplares similares